Clinical framework demonstrates safety and improved tumor response rates in advanced hepatocellular carcinoma, indicating potent synergistic antitumor effects.
New strategies combining yttrium 90 ( 90 Y) radioembolization and immune checkpoint inhibitor therapy for treatment of advanced-stage hepatocellular carcinoma show promising safety and improved tumor response rates, with 90 Y radioembolization modulating the tumor immune microenvironment and enhancing responsiveness to immunotherapy.
No takes yet. Share an insight, caveat, or question.
Avritscher et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: